Analysts Set Sensus Healthcare, Inc. (NASDAQ:SRTS) Target Price at $6.88

Sensus Healthcare, Inc. (NASDAQ:SRTS) has been assigned a consensus rating of “Moderate Buy” from the six brokerages that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $6.8750.

A number of research analysts recently weighed in on the stock. Weiss Ratings reissued a “sell (d)” rating on shares of Sensus Healthcare in a report on Tuesday. Maxim Group decreased their price target on shares of Sensus Healthcare from $8.00 to $6.00 and set a “buy” rating on the stock in a research note on Tuesday, February 17th. Alliance Global Partners assumed coverage on shares of Sensus Healthcare in a research report on Friday, March 6th. They set a “buy” rating and a $7.50 price objective for the company. Finally, Wall Street Zen cut shares of Sensus Healthcare from a “hold” rating to a “sell” rating in a research note on Saturday, February 14th.

Sensus Healthcare Trading Down 2.7%

Shares of Sensus Healthcare stock opened at $3.93 on Tuesday. The firm has a market cap of $64.69 million, a PE ratio of -8.36 and a beta of 1.28. The stock has a 50 day moving average of $4.12 and a 200 day moving average of $4.11. Sensus Healthcare has a 12 month low of $3.03 and a 12 month high of $5.92.

Sensus Healthcare (NASDAQ:SRTS) last released its quarterly earnings data on Thursday, February 12th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.10). The firm had revenue of $4.94 million during the quarter, compared to the consensus estimate of $8.35 million. Sensus Healthcare had a negative return on equity of 15.11% and a negative net margin of 28.09%.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Opes Wealth Management LLC purchased a new stake in Sensus Healthcare during the third quarter valued at approximately $50,000. XTX Topco Ltd bought a new position in shares of Sensus Healthcare during the 4th quarter valued at approximately $77,000. Jane Street Group LLC purchased a new stake in Sensus Healthcare during the 4th quarter valued at $79,000. Mindset Wealth Management LLC raised its holdings in Sensus Healthcare by 28.1% during the 3rd quarter. Mindset Wealth Management LLC now owns 50,100 shares of the company’s stock valued at $157,000 after buying an additional 11,000 shares during the period. Finally, Ingalls & Snyder LLC bought a new stake in Sensus Healthcare in the fourth quarter worth $219,000. Hedge funds and other institutional investors own 25.30% of the company’s stock.

About Sensus Healthcare

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.